The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Corcept Therapeutics's Revenue for the
three
months ended in Mar. 2026 was €142.6 Mil. Corcept Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was €42.4 Mil.
Hence, Corcept Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.36.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Corcept Therapeutics Receivables Turnover Related Terms
Corcept Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:HTD vs PRAX, IBRX, NUVL: Receivables Turnover Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (HAM:HTD) has a Receivables Turnover of 3.36 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Corcept Therapeutics and its competitors. According to the industry distribution chart, Corcept Therapeutics ranks #122 out of 841 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Corcept Therapeutics' Receivables Turnover too high?
Corcept Therapeutics' current Receivables Turnover is 3.36. The Biotechnology industry median Receivables Turnover is 5.27. Corcept Therapeutics' value of 3.36 is 36.2% below this industry median. Based on the distribution chart, Corcept Therapeutics ranks #122 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Receivables Turnover compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #122 out of 841 companies for Receivables Turnover. This places Corcept Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Corcept Therapeutics' value of 3.36 is 36.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Receivables Turnover of 3.36 is 36.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Receivables Turnover is 3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Receivables Turnover of 3.36. The stock's GF Value™ is €54.59, compared to a current price of €78.94 — trading 44.6% above its estimated fair value. The current Receivables Turnover is 3.36 and 36.2% below the Biotechnology industry median of 5.27. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Receivables Turnover is 3.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €78.94 is trading 44.6% above its estimated GF Value™ of €54.59.
Key valuation signals for HAM:HTD:
Receivables Turnover: 3.36
GF Value™: €54.59 vs. price of €78.94 (44.6% above fair value)
Industry Position: 36.2% below the Biotechnology median (#122 of 841)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score
Get the complete analysis for HAM:HTD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
